Fatih Erkam Olgun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fatih Erkam Olgun has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Ümeyir Savur
Department of Cardiology, Medipol Mega University Hospital, Istanbul Medipol University, 34214 Istanbul, Turkey
7 shared publications - Fethi Kılıçaslan
Department of Cardiology, Faculty of Medicine, İstanbul Medipol University, İstanbul, Türkiye
6 shared publications - Aykun Hakgor
Department of Cardiology, Faculty of Medicine Medipol University Istanbul Turkey
4 shared publications - Aysel Akhundova
Department of Cardiology, Medipol Mega University Hospital, Istanbul Medipol University, 34214 Istanbul, Turkey
4 shared publications - Haci Murat Gunes
Department of Cardiology, Medipol Mega University Hospital, Istanbul Medipol University, 34214 Istanbul, Turkey
4 shared publications - Atakan Dursun
Department of Cardiology, Istanbul Medipol University, Medipol Mega University Hospital, 34214 Istanbul, Türkiye
3 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Springer Nature in BMC Primary Care
- Vol. 27 (1)
Prevalence of ECG-detected and previously unrecognized atrial fibrillation among older adults attending a family health center: a single-center cross-sectional screening study
Atrial fibrillation (AF) is an important and often unrecognized cause of ischemic stroke in older adults. The primary objective of this study was to determ
- 11 September 2026
- Published by Springer Nature in BMC Primary Care
- Vol. 27 (1)
Open AccessPrevalence of ECG-detected and previously unrecognized atrial fibrillation among older adults attending a family health center: a single-center cross-sectional screening study
Atrial fibrillation (AF) is an important and often unrecognized cause of ischemic stroke in older adults. The primary objective of this study was to determ
- Open Access
SGLT2 Inhibitor Therapy and Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Patients with Low Ejection Fraction
Background and Objectives: Patients with impaired left ventricular ejection fraction (LVEF) undergoing transcatheter aortic valve implantation (TAVI) remain at high risk for adverse outcomes despite successful procedures. Sodium–glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes in heart failure, but their long-term impact after TAVI is not well established. Materials and Methods: This single-center retrospective study included patients with LVEF < 50% who underwent transfemoral TAVI between January 2015 and September 2025. Patients were stratified according to SGLT2i use. The primary outcome was a composite of all-cause mortality and heart failure (HF) hospitalization requiring intravenous diuretics. Secondary outcomes included all-cause mortality, HF hospitalization, and changes in echocardiographic parameters at 6 months. Inverse probability of treatment weighting (IPTW) based on propensity scores was applied to adjust for baseline differences. Time-to-event analyses were performed using IPTW-weighted Cox models and adjusted survival curves. Results: The study included 226 patients (78 SGLT2i users, 148 non-users) with a median follow-up of 37 months. After IPTW adjustment, SGLT2i use was associated with a lower rate of the composite outcome (32.8% vs. 50.8%, p = 0.019) and a lower crude long-term mortality (32.8% vs. 47.4%, p = 0.056). Acute kidney injury after TAVI occurred less frequently among SGLT2i users (3.4% vs. 17.4%, p = 0.013). In IPTW-weighted Cox analyses, SGLT2i use was associated with a reduced risk of all-cause mortality (HR 0.57, 95% CI 0.32–0.98) and the composite outcome (HR 0.56, 95% CI 0.33–0.96). SGLT2i users demonstrated greater reductions in left ventricular end-diastolic diameter at 6 months. Conclusions: In patients with impaired LVEF undergoing TAVI, SGLT2 inhibitor therapy was associated with improved long-term survival, better composite outcome-free survival, and lower rates of post-TAVI acute kidney injury. Larger prospective studies are warranted to confirm these findings.
Open AccessSGLT2 Inhibitor Therapy and Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Patients with Low Ejection Fraction
Background and Objectives: Patients with impaired left ventricular ejection fraction (LVEF) undergoing transcatheter aortic valve implantation (TAVI) remain at high risk for adverse outcomes despite successful procedures. Sodium–glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes in heart failure, but their long-term impact after TAVI is not well established. Materials and Methods: This single-center retrospective study included patients with LVEF < 50% who underwent transfemoral TAVI between January 2015 and September 2025. Patients were stratified according to SGLT2i use. The primary outcome was a composite of all-cause mortality and heart failure (HF) hospitalization requiring intravenous diuretics. Secondary outcomes included all-cause mortality, HF hospitalization, and changes in echocardiographic parameters at 6 months. Inverse probability of treatment weighting (IPTW) based on propensity scores was applied to adjust for baseline differences. Time-to-event analyses were performed using IPTW-weighted Cox models and adjusted survival curves. Results: The study included 226 patients (78 SGLT2i users, 148 non-users) with a median follow-up of 37 months. After IPTW adjustment, SGLT2i use was associated with a lower rate of the composite outcome (32.8% vs. 50.8%, p = 0.019) and a lower crude long-term mortality (32.8% vs. 47.4%, p = 0.056). Acute kidney injury after TAVI occurred less frequently among SGLT2i users (3.4% vs. 17.4%, p = 0.013). In IPTW-weighted Cox analyses, SGLT2i use was associated with a reduced risk of all-cause mortality (HR 0.57, 95% CI 0.32–0.98) and the composite outcome (HR 0.56, 95% CI 0.33–0.96). SGLT2i users demonstrated greater reductions in left ventricular end-diastolic diameter at 6 months. Conclusions: In patients with impaired LVEF undergoing TAVI, SGLT2 inhibitor therapy was associated with improved long-term survival, better composite outcome-free survival, and lower rates of post-TAVI acute kidney injury. Larger prospective studies are warranted to confirm these findings.
- 1 January 2026
- Published by Kare Publishing in The Anatolian Journal of Cardiology
Comparison of Cryoballoon and Pulsed Field Ablation in Patients with Symptomatic Atrial Fibrillation: First 6-Month Experience
Background: Catheter ablation is an effective treatment for patients with symptomatic atrial fibrillation (AF), and pulmonary vein isolation (PVI) is the cornerstone of AF ablation. Unlike thermal ablation, pulsed field ablation (PFA) uses nonthermal energy to irreversibly electroporate myocardial tissue without affecting adjacent structures such as the esophagus, phrenic nerve, and PV tissue. The aim of this study was to compare the efficacy and safety of the 2 most widely used single-shot ablation techniques worldwide: Cryoballoon (CB) and PFA. To date, this is the first PFA study to be published from Türkiye. Methods: Consecutive AF patients who underwent PFA and CB-based PVI between July 2025 and February 2026 were enrolled. Cryoballoon PVI was performed using the 28-mm CB; PFA was performed using a 31 mm pentaspline catheter under fluoroscopic guidance. Results: A total of 100 patients were included in the study (66% male, 64% with paroxysmal AF, mean age: 61.7 ± 11.8 years). There were 55 patients in the CB group and 45 patients in the PFA group. The skin-to-figure-of-8 time was significantly shorter in the PFA group than in the CB group (30.00 [25.00-35.00] vs. 53.00 [47.00-55.00] minutes, P < .001). No cerebrovascular events, groin complications, or pericardial effusions were observed in patients in either group. During the 6-month follow-up period, 4 (8.9%) cases of atrial arrhythmia were observed in the PFA group, compared to 7 (12.7%) in the CB group (P = .406). Conclusion: Both CB and PFA are safe and effective treatment methods for symptomatic patients diagnosed with AF. Compared to CB, acute procedure success rates and complications are similar in PFA, but procedure times are shorter.
- 1 January 2026
- Published by Kare Publishing in The Anatolian Journal of Cardiology
Comparison of Cryoballoon and Pulsed Field Ablation in Patients with Symptomatic Atrial Fibrillation: First 6-Month Experience
Background: Catheter ablation is an effective treatment for patients with symptomatic atrial fibrillation (AF), and pulmonary vein isolation (PVI) is the cornerstone of AF ablation. Unlike thermal ablation, pulsed field ablation (PFA) uses nonthermal energy to irreversibly electroporate myocardial tissue without affecting adjacent structures such as the esophagus, phrenic nerve, and PV tissue. The aim of this study was to compare the efficacy and safety of the 2 most widely used single-shot ablation techniques worldwide: Cryoballoon (CB) and PFA. To date, this is the first PFA study to be published from Türkiye. Methods: Consecutive AF patients who underwent PFA and CB-based PVI between July 2025 and February 2026 were enrolled. Cryoballoon PVI was performed using the 28-mm CB; PFA was performed using a 31 mm pentaspline catheter under fluoroscopic guidance. Results: A total of 100 patients were included in the study (66% male, 64% with paroxysmal AF, mean age: 61.7 ± 11.8 years). There were 55 patients in the CB group and 45 patients in the PFA group. The skin-to-figure-of-8 time was significantly shorter in the PFA group than in the CB group (30.00 [25.00-35.00] vs. 53.00 [47.00-55.00] minutes, P < .001). No cerebrovascular events, groin complications, or pericardial effusions were observed in patients in either group. During the 6-month follow-up period, 4 (8.9%) cases of atrial arrhythmia were observed in the PFA group, compared to 7 (12.7%) in the CB group (P = .406). Conclusion: Both CB and PFA are safe and effective treatment methods for symptomatic patients diagnosed with AF. Compared to CB, acute procedure success rates and complications are similar in PFA, but procedure times are shorter.
- 28 August 2025
- Published by Mugla Sitki Kocman University in Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi
- Vol. 12 (2) , 105-112
The Evaluation of Lesion Localization and Ischemic Myocardial Mass Via Arrhythmia Parameters in Stable Coronary Artery Patients with Myocardial Ischemia
The aim of this study was to evaluate which critical coronary artery stenosis is more arrhythmogenic in stable coronary artery disease and whether the involved stenotic artery or the size of the myocardial tissue under ischemia due to stenosis is more important in terms of malignant ventricular arrhythmias by using arrhythmia predictors calculated on electrocardiography. This was a retrospective observational study. We scanned patients who underwent percutaneous coronary intervention for single vessel stable coronary artery disease between January 2013 and 2016. Assigned indicators of increased arrhythmogenic risk as TpTe interval, QTc interval and TpTe/QT ratio were calculated on electrocardiography before and after the percutaneous coronary intervention. We also calculated the anatomical myocardial area at risk of ischemia as a percentage of the left ventricular myocardium volume for a given site of lesion with APPROACH score by assessing coronary angiography images. The percentage of left ventricular jeopardized myocardium in left anterior descending artery lesions (34±10) was significantly higher than those in circumflex artery (17±11) and right coronary artery (21±5) lesions (p<0.001). Furthermore, the differences between TpTe intervals and TpTe/QT ratios measured before and after the percutaneous coronary intervention were significantly higher in patients with left anterior descending artery lesions than patients with circumflex artery and right coronary artery lesions (p<0.001). In patients with stable coronary artery disease, the size of the ischemic myocardium was associated with increased arrhythmogenesis. Patients with left anterior descending artery lesions may get the greatest benefit from revascularization in terms of arrhythmia predictors calculated on electrocardiography.
- 28 August 2025
- Published by Mugla Sitki Kocman University in Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi
- Vol. 12 (2) , 105-112
The Evaluation of Lesion Localization and Ischemic Myocardial Mass Via Arrhythmia Parameters in Stable Coronary Artery Patients with Myocardial Ischemia
The aim of this study was to evaluate which critical coronary artery stenosis is more arrhythmogenic in stable coronary artery disease and whether the involved stenotic artery or the size of the myocardial tissue under ischemia due to stenosis is more important in terms of malignant ventricular arrhythmias by using arrhythmia predictors calculated on electrocardiography. This was a retrospective observational study. We scanned patients who underwent percutaneous coronary intervention for single vessel stable coronary artery disease between January 2013 and 2016. Assigned indicators of increased arrhythmogenic risk as TpTe interval, QTc interval and TpTe/QT ratio were calculated on electrocardiography before and after the percutaneous coronary intervention. We also calculated the anatomical myocardial area at risk of ischemia as a percentage of the left ventricular myocardium volume for a given site of lesion with APPROACH score by assessing coronary angiography images. The percentage of left ventricular jeopardized myocardium in left anterior descending artery lesions (34±10) was significantly higher than those in circumflex artery (17±11) and right coronary artery (21±5) lesions (p<0.001). Furthermore, the differences between TpTe intervals and TpTe/QT ratios measured before and after the percutaneous coronary intervention were significantly higher in patients with left anterior descending artery lesions than patients with circumflex artery and right coronary artery lesions (p<0.001). In patients with stable coronary artery disease, the size of the ischemic myocardium was associated with increased arrhythmogenesis. Patients with left anterior descending artery lesions may get the greatest benefit from revascularization in terms of arrhythmia predictors calculated on electrocardiography.
- 1 March 2025
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 85 (3) , 225-232
Sodium Glucose Cotransporter 2 Inhibitors Improve Long-term Atrial Fibrillation-free Survival After Catheter Ablation
Although sodium–glucose cotransporter 2 inhibitors (SGLT2i) are known to reduce the incidence of atrial fibrillation (AF) and AF-related adverse events, evidence on their prognostic effect in patients undergoing catheter ablation (CA) for AF is limited. In a single center, 614 patients (mean age 58.1 ± 9.9 years, 42.2% female) who underwent CA for AF were retrospectively divided into 2 groups according to SGLT2i treatment after the index procedure and followed up for 24 months. The primary outcome of the study was AF recurrence after the first 90-day blanking period after CA. Two separate Cox regression models were constructed to determine the predictors of AF recurrence. Rates of the primary outcome were 19.4% and 35.7% in the SGLT2i and non-SGLT2i groups, respectively. According to the multivariable model 1, which was established among the clinically relevant variables that were found to be statistically significant in univariable analysis, left atrial diameter (adjusted HR: 1.087, 95% CI, 1.054–1.122, P < 0.001), SGLT2i therapy (adjusted HR: 0.436, 95% CI, 0.286–0.665, P < 0.001), and nonparoxysmal AF (adjusted HR: 1.549, 95% CI, 1.039–2.309, P = 0.032) were independent predictors of recurrence after ablation. In model 2, SGLT2i treatment remained an independent predictor of AF recurrence along with significant variables such as age, heart failure with reduced ejection fraction, and previous stroke (adjusted HR: 0.315, 95% CI, 0.214–0.461, P < 0.001). The favorable efficacy of SGLT2i on the primary outcome was maintained in subgroup analyses. SGLT2i treatment is associated with lower recurrence after CA for AF in subgroups with and without diabetes or heart failure with reduced ejection fraction and in the overall patient population, independent of AF phenotype.
- 1 March 2025
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 85 (3) , 225-232
Sodium Glucose Cotransporter 2 Inhibitors Improve Long-term Atrial Fibrillation-free Survival After Catheter Ablation
Although sodium–glucose cotransporter 2 inhibitors (SGLT2i) are known to reduce the incidence of atrial fibrillation (AF) and AF-related adverse events, evidence on their prognostic effect in patients undergoing catheter ablation (CA) for AF is limited. In a single center, 614 patients (mean age 58.1 ± 9.9 years, 42.2% female) who underwent CA for AF were retrospectively divided into 2 groups according to SGLT2i treatment after the index procedure and followed up for 24 months. The primary outcome of the study was AF recurrence after the first 90-day blanking period after CA. Two separate Cox regression models were constructed to determine the predictors of AF recurrence. Rates of the primary outcome were 19.4% and 35.7% in the SGLT2i and non-SGLT2i groups, respectively. According to the multivariable model 1, which was established among the clinically relevant variables that were found to be statistically significant in univariable analysis, left atrial diameter (adjusted HR: 1.087, 95% CI, 1.054–1.122, P < 0.001), SGLT2i therapy (adjusted HR: 0.436, 95% CI, 0.286–0.665, P < 0.001), and nonparoxysmal AF (adjusted HR: 1.549, 95% CI, 1.039–2.309, P = 0.032) were independent predictors of recurrence after ablation. In model 2, SGLT2i treatment remained an independent predictor of AF recurrence along with significant variables such as age, heart failure with reduced ejection fraction, and previous stroke (adjusted HR: 0.315, 95% CI, 0.214–0.461, P < 0.001). The favorable efficacy of SGLT2i on the primary outcome was maintained in subgroup analyses. SGLT2i treatment is associated with lower recurrence after CA for AF in subgroups with and without diabetes or heart failure with reduced ejection fraction and in the overall patient population, independent of AF phenotype.
- Open Access
- 1 January 2024
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 28 (12) , 575-583
Transseptal Puncture and Cryoballoon Ablation of Atrial Fibrillation in Patients with Atrial Septal Occluder or Atrial Septal Defect Surgical Repair: A Single Center Experience
Background: Atrial fibrillation (AF) is a common arrhythmia in patients with atrial septal defect (ASD). Cryoballoon ablation (CA) is a safe and efficient method for pulmonary vein (PV) isolation in the treatment of AF. Achieving left atrial access may be difficult in patients with atrial septal occluders (ASO) or surgical repair of ASD. The aim of this study was to present our experience with the efficacy and safety of transseptal puncture and AF ablation in CA in this subset of patients. Methods: We retrieved our data about patients with ASO or surgical repair of ASD undergoing cryoballoon AF ablation procedures at our center between August 2019 and January 2022. Results: Nine patients (age 43.88 ± 9.73 years) with AF (5 paroxysmal and 4 persistent) and ASO or surgical repair of ASD were enrolled. All three patients had a 28 mm Amplatzer ASO device which occupied the whole septum, and direct puncture through the ASO was performed. Sequential balloon dilatation was performed in 2 patients with surgical ASD repair and all 3 patients with ASO. Four of 6 patients (66.7%) in the surgical repair group required transesophageal echocardiography during transseptal puncture. The endpoint of the procedure, isolation of all PVs, was achieved in all 9 patients. None of the patients had evidence of an interatrial shunt or pericardial effusion at the end of the procedure. Total procedural time (123 ± 28 minutes vs. 63 ± 21 minutes, P = .024) and total fluoroscopy time (41 ± 5 minutes vs. 23 ± 8 minutes, P = .024) were significantly higher in the percutaneous closure group. Conclusions: In patients with ASO or surgical repair of ASD, CA of AF might be feasible, safe, and effective. The balloon dilatation of the interatrial septum (IAS) might assist transseptal access through the ASO or a surgically repaired thickened IAS.
- 1 January 2024
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 28 (12) , 575-583
Open AccessTransseptal Puncture and Cryoballoon Ablation of Atrial Fibrillation in Patients with Atrial Septal Occluder or Atrial Septal Defect Surgical Repair: A Single Center Experience
Background: Atrial fibrillation (AF) is a common arrhythmia in patients with atrial septal defect (ASD). Cryoballoon ablation (CA) is a safe and efficient method for pulmonary vein (PV) isolation in the treatment of AF. Achieving left atrial access may be difficult in patients with atrial septal occluders (ASO) or surgical repair of ASD. The aim of this study was to present our experience with the efficacy and safety of transseptal puncture and AF ablation in CA in this subset of patients. Methods: We retrieved our data about patients with ASO or surgical repair of ASD undergoing cryoballoon AF ablation procedures at our center between August 2019 and January 2022. Results: Nine patients (age 43.88 ± 9.73 years) with AF (5 paroxysmal and 4 persistent) and ASO or surgical repair of ASD were enrolled. All three patients had a 28 mm Amplatzer ASO device which occupied the whole septum, and direct puncture through the ASO was performed. Sequential balloon dilatation was performed in 2 patients with surgical ASD repair and all 3 patients with ASO. Four of 6 patients (66.7%) in the surgical repair group required transesophageal echocardiography during transseptal puncture. The endpoint of the procedure, isolation of all PVs, was achieved in all 9 patients. None of the patients had evidence of an interatrial shunt or pericardial effusion at the end of the procedure. Total procedural time (123 ± 28 minutes vs. 63 ± 21 minutes, P = .024) and total fluoroscopy time (41 ± 5 minutes vs. 23 ± 8 minutes, P = .024) were significantly higher in the percutaneous closure group. Conclusions: In patients with ASO or surgical repair of ASD, CA of AF might be feasible, safe, and effective. The balloon dilatation of the interatrial septum (IAS) might assist transseptal access through the ASO or a surgically repaired thickened IAS.
- Open Access
- 1 April 2022
- Published by Kosuyolu Heart Journal, Health Sciences University in Kosuyolu Heart Journal
- Vol. 25 (1) , 85-94
Relationship Between Autonomic Nervous System Activity and Recurrence After Cryoballoon Ablation in Patients with Paroxysmal Atrial Fibrillation
Introduction: In this study, we aimed to investigate the relationship between autonomic dysfunction (AD) determined according to the blood pressure (BP) and heart rate (HR) response in exercise treadmill test (ETT) prior to cryoballoon ablation (CBA), and the recurrence of atrial fibrillation (AF) after CBA in patients with paroxysmal AF. Patients and Methods: Seventy-six patients (mean age 53 ± 11 years, 61.8% male) with paroxysmal AF who underwent CBA were enrolled. Before CBA the ETT was performed by all patients. BP and HR responses in ETT were compared between patients with and without AF recurrence. Results: AD rate was significantly higher in the group with recurrence compared to the non-recurrent group (p< 0.001). In addition to AD, age, female gender, and lower exercise capacity were also associated with post-CBA AF recurrence (p> 0.05 for all). Examining AD parameters, systolic blood pressure at peak exercise (SBPpeak) (p< 0.001) and diastolic blood pressure at peak exercise (DBPpeak) (p< 0.001), slow heart rate recovery (HRR) (p< 0.001) were significantly higher in the recurrent group. Conclusion: AD may be associated with AF recurrence after CBA in patients with paroxysmal AF. SBPpeak, DBPpeak, and slow HRR appear to be predictors of AF recurrence after ablation.
- 1 April 2022
- Published by Kosuyolu Heart Journal, Health Sciences University in Kosuyolu Heart Journal
- Vol. 25 (1) , 85-94
Open AccessRelationship Between Autonomic Nervous System Activity and Recurrence After Cryoballoon Ablation in Patients with Paroxysmal Atrial Fibrillation
Introduction: In this study, we aimed to investigate the relationship between autonomic dysfunction (AD) determined according to the blood pressure (BP) and heart rate (HR) response in exercise treadmill test (ETT) prior to cryoballoon ablation (CBA), and the recurrence of atrial fibrillation (AF) after CBA in patients with paroxysmal AF. Patients and Methods: Seventy-six patients (mean age 53 ± 11 years, 61.8% male) with paroxysmal AF who underwent CBA were enrolled. Before CBA the ETT was performed by all patients. BP and HR responses in ETT were compared between patients with and without AF recurrence. Results: AD rate was significantly higher in the group with recurrence compared to the non-recurrent group (p< 0.001). In addition to AD, age, female gender, and lower exercise capacity were also associated with post-CBA AF recurrence (p> 0.05 for all). Examining AD parameters, systolic blood pressure at peak exercise (SBPpeak) (p< 0.001) and diastolic blood pressure at peak exercise (DBPpeak) (p< 0.001), slow heart rate recovery (HRR) (p< 0.001) were significantly higher in the recurrent group. Conclusion: AD may be associated with AF recurrence after CBA in patients with paroxysmal AF. SBPpeak, DBPpeak, and slow HRR appear to be predictors of AF recurrence after ablation.
- 27 July 2021
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 44 (9) , 1516-1522
Impact of surgical weight loss on novel P‐wave‐related variables which are nominated as predictors of atrial arrhythmias
Background Bariatric surgery has been associated with reduced cardiovascular mortality and morbidity in obese patients. In this study, we aimed to evaluate the alterations of novel P-wave related atrial arrhythmia predictors in patients who achieved effective weight loss with bariatric surgery. Methods The study included 58 patients who underwent bariatric surgery. We measured heart rate, PR, P wave (PW) max, PW min, Average P axis, P wave peak time (PWPT) in lead D2 and lead V1, terminal force in lead V1 (V1TF), and we estimated P wave dispersion (PWdis) interval both pre-operation and 6 months after operation. Results Heart rate, PR, PW max, PW min, PWdis, Average P axis, PWPTD2, PWPTV1 and V1TF values, which were close to the upper limit in the pre-op period, showed statistically significant decreases at 6 months after the operation. The most prominent changes were observed in PW dis (51.15 ± 9.70 ms vs. 48.79 ± 9.50 ms, p = .010), PWPTD2 (55.75 ± 6.91 ms vs. 50.59 ± 7.67 ms, p < .001), PWPTV1 (54.10 ± 7.06 ms vs. 48.05 ± 7.64 ms, p < .001) and V1TF (25 [43.1%] vs. 12 [20.7%], p < .001). Conclusions The results of our study indicated that bariatric surgery has positive effects on the regression of ECG parameters which are predictors of atrial arrhythmias, particularly atrial fibrillation (AF).
- 27 July 2021
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 44 (9) , 1516-1522
Impact of surgical weight loss on novel P‐wave‐related variables which are nominated as predictors of atrial arrhythmias
Background Bariatric surgery has been associated with reduced cardiovascular mortality and morbidity in obese patients. In this study, we aimed to evaluate the alterations of novel P-wave related atrial arrhythmia predictors in patients who achieved effective weight loss with bariatric surgery. Methods The study included 58 patients who underwent bariatric surgery. We measured heart rate, PR, P wave (PW) max, PW min, Average P axis, P wave peak time (PWPT) in lead D2 and lead V1, terminal force in lead V1 (V1TF), and we estimated P wave dispersion (PWdis) interval both pre-operation and 6 months after operation. Results Heart rate, PR, PW max, PW min, PWdis, Average P axis, PWPTD2, PWPTV1 and V1TF values, which were close to the upper limit in the pre-op period, showed statistically significant decreases at 6 months after the operation. The most prominent changes were observed in PW dis (51.15 ± 9.70 ms vs. 48.79 ± 9.50 ms, p = .010), PWPTD2 (55.75 ± 6.91 ms vs. 50.59 ± 7.67 ms, p < .001), PWPTV1 (54.10 ± 7.06 ms vs. 48.05 ± 7.64 ms, p < .001) and V1TF (25 [43.1%] vs. 12 [20.7%], p < .001). Conclusions The results of our study indicated that bariatric surgery has positive effects on the regression of ECG parameters which are predictors of atrial arrhythmias, particularly atrial fibrillation (AF).
- Open Access
- 2 July 2021
- Published by Turkish Society of Cardiology in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
- Vol. 49 (5) , 357-367
Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey. The ARNi-TR is a multicenter, noninterventional, retrospective, observational study. Overall, 779 patients with HF from 22 centers in Turkey who were prescribed sacubitril/valsartan were examined. Initial clinical status, biochemical and echocardiographic parameters, and New York Heart Association functional class (NYHA-FC) values were compared with follow-up values after 1 year of ARNi use. In addition, the effect of ARNi on number of annual hospitalizations was investigated, and the patients were divided into 2 groups, depending on whether ARNi was initiated at hospitalization or under outpatient clinic control. N-terminal pro-brain natriuretic peptide (NT-proBNP), left-ventricle ejection fraction (LV-EF), and NYHA-FC values improved significantly in both groups (all parameters, p<0.001) within 1-year follow-up. In both groups, a decrease in hemoglobin A1c (HbA1c) values was observed in ARNi use (p<0.001), and a decrease in daily diuretic doses and hospitalizations owing to HF were observed after ARNi use (all comparisons, p<0.001). Hypertension (16.9%) was the most common side effect in patients using ARN. The ARNi-TR study offers comprehensive real-life data for patients using ARNi in Turkey. The use of ARNi has shown significant improvements in FC, NT-proBNP, HbA1c levels, and LV-EF. Likewise, reductions in the number of annual hospitalizations and daily furosemide doses for HF were seen in this study.
- 2 July 2021
- Published by Turkish Society of Cardiology in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
- Vol. 49 (5) , 357-367
Open AccessAngiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey. The ARNi-TR is a multicenter, noninterventional, retrospective, observational study. Overall, 779 patients with HF from 22 centers in Turkey who were prescribed sacubitril/valsartan were examined. Initial clinical status, biochemical and echocardiographic parameters, and New York Heart Association functional class (NYHA-FC) values were compared with follow-up values after 1 year of ARNi use. In addition, the effect of ARNi on number of annual hospitalizations was investigated, and the patients were divided into 2 groups, depending on whether ARNi was initiated at hospitalization or under outpatient clinic control. N-terminal pro-brain natriuretic peptide (NT-proBNP), left-ventricle ejection fraction (LV-EF), and NYHA-FC values improved significantly in both groups (all parameters, p<0.001) within 1-year follow-up. In both groups, a decrease in hemoglobin A1c (HbA1c) values was observed in ARNi use (p<0.001), and a decrease in daily diuretic doses and hospitalizations owing to HF were observed after ARNi use (all comparisons, p<0.001). Hypertension (16.9%) was the most common side effect in patients using ARN. The ARNi-TR study offers comprehensive real-life data for patients using ARNi in Turkey. The use of ARNi has shown significant improvements in FC, NT-proBNP, HbA1c levels, and LV-EF. Likewise, reductions in the number of annual hospitalizations and daily furosemide doses for HF were seen in this study.